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Background: Injecting drug users (IDUs) in Taiwan contributed significantly to an HIV/AIDS epidemic in 2005. In
addition, studies that identified risk factors of HCV/HIV co-infection among IDUs were sparse. This study aimed to
identify risk factors of HCV/HIV co-infection and HCV mono-infection, as compared with seronegativity, among
injecting drug users (IDUs) at a large methadone maintenance treatment program (MMTP) in Taipei, Taiwan.
Methods: Data from enrollment interviews and HCV and HIV testing completed by IDUs upon admission to the
Taipei City Hospital MMTP from 2006–2010 were included in this cross-sectional analysis. HCV and HIV testing was
repeated among re-enrollees whose HCV or HIV test results were negative at the preceding enrollment. Backward
stepwise multinomial logistic regression was used to identify risk factors associated with HCV/HIV co-infection and
HCV mono-infection.
Results: Of the 1,447 IDUs enrolled, the prevalences of HCV/HIV co-infection, HCV mono-infection, and HIV
mono-infection were 13.1%, 78.0%, and 0.4%, respectively. In backward stepwise multinomial regression analysis,
after controlling for potential confounders, syringe sharing in the 6 months before MMTP enrollment was
significantly positively associated with HCV/HIV co-infection (adjusted odds ratio [AOR]=27.72, 95% confidence
interval [CI] 13.30–57.76). Incarceration was also significantly positively associated with HCV/HIV co-infection
(AOR=2.01, 95% CI 1.71–2.37) and HCV mono-infection (AOR=1.77, 95% CI 1.52–2.06), whereas smoking
amphetamine in the 6 months before MMTP enrollment was significantly inversely associated with HCV/HIV
co-infection (AOR=0.44, 95% CI 0.25–0.76) and HCV mono-infection (AOR=0.49, 95% CI 0.32–0.75). HCV
seroincidence was 45.25/100 person-years at risk (PYAR; 95% CI 24.74–75.92/100 PYAR) and HIV seroincidence was
0.53/100 PYAR (95% CI 0.06–1.91/100 PYAR) among re-enrolled IDUs who were HCV- or HIV-negative at the
preceding enrollment.
Conclusions: IDUs enrolled in Taipei MMTPs had very high prevalences of HCV/HIV co-infection and HCV
mono-infection. Interventions such as expansion of syringe exchange programs and education regarding
HCV/HIV prevention should be implemented for this high-risk group of drug users.
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Injecting drug users (IDUs) are susceptible to many
blood-borne infections. It is estimated that there are
15.9 million IDUs worldwide [1], among whom 62.9%
were infected with hepatitis C virus (HCV) and 18.9%
with human immunodeficiency virus (HIV) [1,2]. Many
human behaviors, such as unsafe injection practices and
unsafe sexual behaviors, are associated with HCV [3]
and HIV [4,5] infections among IDUs. HCV and HIV
contribute substantially to morbidity and mortality in
this population [2,6]. Moreover, co-infection with HCV
and HIV is not uncommon and has become a global
public health problem, causing an increased rate of pro-
gression to cirrhosis, decompensated liver disease, hepa-
tocellular carcinoma, and death [7,8]. Therefore, it is
crucial to determine the prevalences of HCV/HIV co-
infection and HCV and HIV mono-infection among
IDUs.
In Taiwan, the problem of HCV and HIV infection
among IDUs has received increasing attention. HCV
prevalence appears to be very high among IDUs, with
prevalences estimated at between 59.5% and 89.6% for
IDUs [9-12] as compared with 4.4% among Taiwanese
aged 20 years or older [13]. Additionally, HIV prevalence
was estimated to be between 12.3% and 25.5% among
IDUs, as compared with 0.08% among the general popu-
lation [10,12,14]. Of even greater concern is that from
2003 to 2005 newly reported HIV-positive cases
increased rapidly from 860 to 3381, and the percentage
attributed to IDUs markedly increased from 2.1% to
72.4%. To curb this outbreak, Taiwan’s Centers for Dis-
ease Control (CDC) began a harm reduction program in
2006 that provides syringe exchange services at pharma-
cies and methadone clinics and offers methadone ther-
apy to heroin addicts. Taiwan’s HIV epidemic has slowed
since then—in 2011 the number of newly reported HIV
cases decreased to 1963, and the percentage attributed
to IDUs decreased to 6.4%. However, IDUs still
accounted for 29.9% of all reported HIV cases in Taiwan
at the end of 2011 [14].
The epidemiology of HCV and HIV mono-infection
and HCV/HIV co-infection among IDUs has not been
thoroughly studied, and no study has investigated risk
factors associated with HCV/HIV co-infection in Taiwan.
Only two studies—one in Vancouver [15] and another in
southern China [16]—distinguished between HCV
mono-infection and HCV infection among IDUs. Studies
that attempted to identify risk factors of HCV/HIV co-
infection among IDUs were either limited to male IDUs
[17] or young IDUs (≤29 years of age) [15] or underesti-
mated the effects of co-infection because, instead of
seronegative cases, they enrolled mono-infected cases
[16], or both mono-infected and seronegative cases, as
the reference group [15,17]. Moreover, findings on theassociation between syringe sharing and HCV/HIV co-
infection were not consistent [15-17]. Investigations
about factors associated with HCV and HIV mono-
infection and HCV/HIV co-infection among IDUs are
needed to control the epidemic. Thus, this study aimed
to measure the prevalence, incidence, and correlates of
HCV/HIV co-infection and HCV mono-infection, as
compared with seronegativity, among IDUs at a large
methadone maintenance treatment program (MMTP) in
Taipei, Taiwan in 2006–2010.
Methods
Study setting and population
In this cross-sectional study we reviewed the enrollment
records for all clients at the MMTP of the Kun-Ming
branch of Taipei City Hospital (TCH) between 2006 and
2010. TCH began their MMTP in December 2006 and
voluntarily enrolled Taiwanese drug users with a history
of heroin addiction by any route [14]. TCH serves ap-
proximately 90.6% of all MMTP clients in Taipei [14].
Every day, MMTP clients are required to attend metha-
done stands at hospitals to receive free therapy with
methadone under direct supervision. They are also
required to visit methadone clinics for counseling every
month. Those who do not attend methadone stands for
2 weeks or longer are removed from the therapy list. If
they seek re-enrollment, they are required to pay the
equivalent of US$100 for biological testing. At TCH, the
retention rate among MMTP clients was 60.7% and
43.4% at 6 and 12 months after enrollment, respectively
[14]. All MMTP participants who had injected drugs in
the 6 months before MMTP enrollment between 2006
and 2010 were included in this study. All MMTP clients
who used only inhaled drugs were excluded from the
analysis. This study was approved by the Institutional
Review Board of TCH. All enrollees were anonymous.
Data collection
At the time of enrollment, each MMTP participant com-
pleted a face-to-face interview conducted by trained
case managers using a standardized questionnaire. The
information collected included sociodemographic
characteristics (i.e., age, gender, marital status, education,
employment status, principal source of income in the 6
months before MMTP enrollment, living situation, num-
ber of MMTP enrollments, and history and frequency of
incarceration) and substance use histories (i.e., age at
first drug use, types of drugs used, syringe sharing in the
6 months before MMTP enrollment, types of drugs used
in the 6 months before MMTP enrollment, and any al-
cohol use in the 6 months before MMTP enrollment).
Principal source of income was classified as regular em-
ployment, social welfare or family, or other, including
savings and friends. Living situation included living with
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drugs used included heroin, amphetamine, marijuana,
and others. For re-enrollees, data from their most recent
interviews were used in the analysis. The existing dataset
contained an identifier to indicate whether an individual
was a re-enrollee. This identifier was coded by TCH
prior to the data release and not by the researchers.
Biological testing
At enrollment, MMTP clients are required to undergo
serologic testing for HCV and HIV antibodies and urine
drug screening. HCV and HIV antibody testing was per-
formed by Kun-Ming Laboratory (Taipei, Taiwan). HCV
antibody (anti-HCV) testing was done with a chemilu-
minescence immunoassay (Architect i 2000 version 3.0,
Abbott Diagnostics) [18]. HIV testing was done with an
enzyme-linked immunosorbent assay (Genscreen HIV1/
2 version 2) followed by Western blot confirmation of
reactive samples according to standard protocols [19].
Urine drug screening consisted of a competitive immu-
nochromatography test (Firstep Bioresearch, Inc.) [20].
MMTP clients were required to visit MMTP clinics 1
week after enrollment to receive the above test results
and associated counseling as well as referrals for clinical
care if needed. In Taiwan, the government, together with
the national health insurance program, covers HCV and
HIV treatment. Re-enrolled participants underwent re-
peat HCV and HIV testing if they were negative for
HCV or HIV at the preceding enrollment.
Statistical analysis
Prevalences of HCV/HIV co-infection and HCV and
HIV mono-infection were based on the most recent
MMTP enrollment data for the study participants. HCV
and HIV incidences were estimated from re-enrolled
participants who were HCV- or HIV-negative at the pre-
ceding MMTP enrollment. Person-years of follow-up
was used to estimate incidence rate and was calculated
from the baseline to the midpoint between the last nega-
tive and first positive test results.
Study participants were divided into three groups:
HCV/HIV co-infected, HCV mono-infected, and sero-
negative (i.e., negative for both HCV and HIV). Since
the HCV and HIV co-infection is not uncommon in
IDUs and these two infections shared the similar route of
transmission, this study used HCV/HIV seronegativity as
the reference group to determine the factors associated
with HCV mono-infection and HCV/HIV co-infection,
respectively.
In bivariate analysis, variables were analyzed using
means or medians for continuous measures and fre-
quencies and percentages for categorical variables. The
chi-square test was used to assess bivariate associations
of selected factors with HCV/HIV co-infection and HCVand HIV mono-infection. All variables found to be sta-
tistically significant (P < 0.10) in bivariate analysis were
considered for inclusion in multivariable analysis [21].
Backward stepwise multinomial regression analysis was
used because the dependent variable had more than two
discrete outcomes. This yielded a final model that
included factors with a P value < 0.05. Odds ratios
(ORs) and adjusted odds ratios (AORs) with 95% confi-
dence intervals (CIs) are reported in order to show the
strength and direction of associations. Analyses were
done with the SPSS version 19.0 statistical software
package (SPSS, Chicago IL, USA).Results
Description of the study population
A total of 1,447 IDUs participated in the TCH MMTP
from December 2006 through the end of 2010; 13.1%
(190) were HCV/HIV co-infected, 78.0% (1128) were
HCV mono-infected, 0.4% (4) were HIV mono-infected,
and 8.6% (125) were seronegative (Table 1). The 4 HIV
mono-infected cases were excluded from subsequent
analysis because of the small sample size. Among the
remaining 1443 IDUs, the annual numbers of partici-
pants were 3 (0.2%) in 2006, 264 (18.3%) in 2007, 400
(27.7%) in 2008, 445 (30.8%) in 2009, and 331 (22.9%) in
2010. The mean age of the clients was 41 years (standard
deviation, sd: 10); 86% were male; and the mean years of
injecting drug use was 14.3 (sd: 9.7). 294 (20.4%) of the
1,443 study subjects were admitted to the TCH MMTP
twice or more, including 64 HCV/HIV co-infections
(33.7%, 64/190), 217 HCV mono-infections (19.2%, 217/
1128), and 13 seronegativities (10.4%, 13/125) (Chi-
square test for p value <0.001).Covariates of infection: univariate and multinomial
regression analyses
As shown in Table 1, the chi-square test revealed that
the factors significantly positively associated with HCV/
HIV co-infection included age, enrollment during 2009–
2010, primary-school education or less, greater number
of MMTP enrollments, higher frequency of incarceration,
longer duration of injecting drug use, and syringe sharing
in the 6 months before MMTP enrollment. Additionally,
amphetamine positivity on urine testing at enrollment was
significantly inversely associated with co-infection. Vari-
ables significantly positively associated with HCV mono-
infection included age, enrollment during 2009–2010,
primary-school education or less, higher frequency of
incarceration, and longer duration of injecting drug use.
Variables significantly inversely associated with HCV
mono-infection included smoking amphetamine in the
6 months before MMTP enrollment and amphetamine
positivity on urine testing at enrollment.
Table 1 Sociodemographic and substance use characteristics of participants by serologic status
Seronegative (n=125) HCV and HIV co-infection (n=190) HCV-monoinfected (n=1128)
Factors n (%) n (%) OR (95%CI) n (%) OR (95%CI)
Sociodemographics
Age (years), median (IQR) 35 (30–45) 40 (32–47) 1.03 (1.004-1.05) 40 (33–48) 1.04 (1.02-1.06)
Male gender 101 (80.8) 158 (83.2) 1.17 (0.65-2.11) 982 (87.1) 1.60 (0.99-2.58)
Year admitted, 2009-2010 51 (40.8) 111 (58.4) 2.01 (1.27-3.18) 614 (54.4) 1.72 (1.18-2.50)
Married status 25 (20.0) 40 (21.1) 1.07 (0.61-1.87) 247 (21.9) 1.12 (0.71-1.78)
Education level≦Primary school 10 (8.0) 30 (15.8) 2.16 (1.10-4.59) 194 (17.2) 2.39 (1.23-4.64)
Unemployment 67 (53.6) 118 (62.1) 1.42 (0.90-2.24) 652 (57.8) 1.19 (0.82-1.72)
Source of most incomea
Regular employment 77 (61.6) 103 (54.2) 1 689 (61.1) 1
Social welfare/Family 36 (28.8) 70 (36.8) 1.45 (0.88-2.39) 363 (32.2) 1.23 (0.74-1.71)
Others 12 (9.6) 17 (8.9) 1.06 (0.48-2.35) 76 (6.7) 0.71 (0.37-1.36)
Living situation
Live with family 95 (76.0) 134 (70.5) 1 860 (76.2) 1
Live with friends 20 (16.0) 31 (16.3) 1.10 (0.59-2.04) 112 (9.9) 0.62 (0.37-1.04)
Live aloneb 10 (8.0) 25 (13.2) 1.77 (0.81-3.86) 156 (13.8) 1.72 (0.88-3.38)
Lifetime MMTP admissions, mean (range) 1.14 (1–4) 1.41 (1–4) 2.63 (1.57-4.39) 1.22 (1–4) 1.49 (0.94-2.37)
Lifetime incarcerations, median (IQR) 1 (0–2) 4 (2–5) 1.92 (1.64-2.25) 3 (2–5) 1.82 (1.58-2.10)
Substance use histories
Age at first injection drug use ≤20 31 (24.8) 66 (34.7) 1.61 (0.98-2.67) 315 (27.9) 1.18 (0.77-1.80)
Length of drug injection (years), mean (range) 9.28 (1–34) 14.56 (1–49) 1.10 (1.06-1.14) 14.76 (1–64) 1.08 (1.05-1.11)
Shared syringesa 11 (8.8) 135 (71.1) 25.44 (12.71-50.90) 161 (14.3) 1.73 (0.91-3.28)
Smoking amphetaminea 75 (60.0) 106 (55.8) 0.84 (0.53-1.33) 514 (45.6) 0.56 (0.38-0.81)
Smoking Marijuanaa 119 (95.2) 184 (96.8) 1.55 (0.49-4.91) 1081 (95.8) 1.16 (0.49-2.77)
Used cocainea 5 (4.0) 5 (2.6) 0.65 (0.18-2.29) 43 (3.8) 0.95 (0.37-2.45)
Swallowed sedative drugsa 17 (13.6) 28 (14.7) 1.10 (0.57-2.10) 145 (12.9) 0.94 (0.55-1.61)
Any alcohol usea 19 (15.2) 20 (10.5) 0.66 (0.34-1.29) 114 (10.1) 0.63 (0.37-1.06)
Urine morphine testingc 113 (90.4) 167 (87.9) 0.77 (0.37-1.61) 1033 (91.6) 1.16 (0.61-2.17)
Urine amphetamine testingc 72 (57.6) 48 (25.3) 0.46 (0.28-0.74) 829 (73.5) 0.49 (0.34-0.72)
HCV, hepatitis C virus. HIV, human immunodeficiency virus. OR, odds ratio. CI, confidence interval. IQR, interquartile range. MMTP, methadone maintenance
treatment program.
a During the 6 months before enrollment in the MMTP.
b Including one homeless injection drug user.
c At the time of enrollment in the MMTP.
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controlling for study subjects’ sociodemographics and
substance use histories, the odds of HIV infection was
27 times higher (95% CI 13.30–57.76) among IDUs with
syringe sharing in the 6 months before MMTP enroll-
ment than among other IDUs without syringe sharing
(Table 2). Also HCV/HIV co-infection was significantly
positively associated with number of MMTP enrollments
(AOR=2.28, 95% CI 1.33–3.90), and number of times
incarcerated (AOR=2.01, 95% CI 1.71–2.37) and signifi-
cantly inversely associated with smoking amphetamine
in the 6 months before MMTP enrollment (AOR=0.44,
95% CI 0.25–0.76; Table 2). Higher number of timesincarcerated increased the risk of HCV mono-infection
by 1.77 times (95% CI 1.52–2.06). Additionally, HCV
mono-infection was significantly positively associated
with duration of injecting drug use (AOR=1.04, 95% CI
1.01–1.07) and was significantly inversely associated with
smoking amphetamine in the 6 months before MMTP
enrollment (AOR=0.49, 95% CI 0.32–0.75) and amphet-
amine positivity on urine testing at MMTP enrollment
(AOR=0.61, 95% CI 0.40–0.93).
HCV and HIV incidences among re-enrollers
During the study period, 14 HCV seroconversions were
detected among the 24 re-enrolled IDUs who were
Table 2 Demographic and substance use variables
associated with HCV/HIV co-infection and HCV
mono-infection in backward stepwise multinomial
regression analysis
AOR 95%CI
HCV and HIV co-infection
Shared syringesa 27.72 13.30-57.76
Number of MMTP enrollments (per time increase) 2.28 1.33-3.90
Number of times incarcerated (per time increase) 2.01 1.71-2.37
Smoking amphetaminea 0.44 0.25-0.76
HCV mono-infection
Number of times incarcerated (per time increase) 1.77 1.52-2.06
Length of drug injection (per year increase) 1.04 1.01-1.07
Smoking amphetaminea 0.49 0.32-0.75
Positive amphetamine urine drug screenb 0.61 0.40-0.93
Reference is HCV/HIV-seronegative cases.
AOR, adjusted odds ratio. CI, confidence interval. HCV, hepatitis C virus. HIV,
human immunodeficiency virus. MMTP, methadone maintenance treatment
program.
a During the 6 months before enrollment in the MMTP.
b At the time of enrollment in the MMTP.
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yielded a total of 30.9 person-years at risk (PYAR) and a
crude incidence rate of HCV mono-infection of 45.25
(95% CI 24.74–75.92)/100 PYAR. 3 (21.4%) of the 14
HCV seroconverters and 2 (20%) of the 10 still HCV
negativities had syringe sharing in the last 6 months
prior to reentry into the MMTP. Additionally, 2 HIV
seroconversions were detected among the 236 re-
enrolled IDUs who were HIV-negative at the preceding
enrollment, which yielded a total of 378.9 PYAR and a
crude incidence rate of 0.53 (95% CI 0.06-1.91)/100
PYAR. The 2 HIV seroconverters denied sharing syringes
in the last 6 months prior to reentry into MMTP. Fur-
thermore, no HCV/HIV co-infection case was detected
among the 23 re-enrolled IDUs who were negative for
both HCV and HIV at the preceding enrollment. The
small number of seroconversions precluded further ana-
lysis of risk factors for incident HCV and HIV infections.
Discussion
According to the above analysis, we found that the pre-
valences of HCV/HIV co-infection and HCV mono-
infection were high among IDUs enrolled in the Taipei
City Hospital MMTP between 2006 and 2010. After
controlling for other characteristics, syringe sharing in
the 6 months before MMTP enrollment was significantly
positively associated with HCV/HIV co-infection but
not with HCV mono-infection. Additionally, greater
frequency of incarceration was significantly positive-
ly associated with HCV/HIV co-infection and HCV
mono-infection, whereas smoking amphetamine in the
6 months before MMTP enrollment was inverselyassociated with HCV/HIV co-infection and HCV mono-
infection.
Although many studies have investigated the sero-
epidemiology of HCV infection among IDUs in Taiwan
[9-11,22-24], none distinguished between HCV mono-
infection and HCV infection, and only one evaluated
risk factors of HCV infection [11]. Chang et al. found
that younger age and longer duration of injecting drug
use were independently associated with HCV infection
among Taiwanese IDUs; however, because that study
used a combination of HIV mono-infected and sero-
negative cases as the reference group, it may have under-
estimated the effects of HCV infection [11].
A literature review showed that the prevalence of
HCV/HIV co-infection among TCH IDUs (13.1%) was
not much different from that among whole IDUs popu-
lation in China in 2007 (12.7%) [25] but higher than
among incarcerated IDUs in the United States between
2003 and 2004 (4.4%) [26] and lower than among incar-
cerated IDUs in Iran in 2006 (24%) [17]. Although few
studies evaluated the prevalence of HCV mono-infection
among IDUs, overall HCV prevalence (91.1%) was
higher in our study than in prior reports in Taiwan. For
example, HCV prevalence was 59.5–89.6% among incar-
cerated IDUs between 1997 and 2005 [9-11] and 89.2%
among IDUs at the MMTPs in four counties and cities
in 2008 [12]. The present overall HCV prevalence was
also higher than that reported in most other Asian coun-
tries, e.g., 47.8% in India between 2004 and 2006 [27],
60% in China in 2007 [28], and 46% in Vietnam between
2005 and 2006 [29]. This extremely high prevalence of
HCV among IDUs in Taipei must be addressed by effect-
ive HCV prevention and better access to HCV therapy.
Syringe sharing in the 6 months before MMTP
enrollment was strongly associated with HCV/HIV co-
infection in this study. This finding may reflect that
injection practices were the major transmission route
of HCV and HIV infection among IDUs [3,5]. Because
co-infection with HCV and HIV in IDUs has become a
rapidly emerging global public health problem [7,8],
interventions including syringe exchange services and
drugs substitution treatments are imperative to prevent
IDUs from HCV and HIV infections [30].
We found that greater frequency of incarceration was
significantly associated with HCV/HIV co-infection and
HCV mono-infection, which suggests that IDUs with a
history of incarceration were more likely to have risk
behaviors related to blood-borne infection [31]. Future
studies should attempt to identify the risk behaviors that
result in such infections.
Smoking amphetamine in the 6 months before MMTP
enrollment was significantly inversely associated with
HCV/HIV co-infection and HCV mono-infection. Am-
phetamine and opiates (e.g., heroin and morphine) have
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smoked amphetamine would be less likely to inject opi-
ates and consequently would have fewer injection risk
behaviors and a lower risk of HCV/HIV co-infection and
HCV mono-infection. This finding supports the harm
reduction policy of providing clean syringes and metha-
done substitution treatment for IDUs.
HCV incidence among re-enrolled IDUs who were
HCV-negative at the preceding MMTP enrollment was
45.25/100 PYAR in this study. HIV incidence among re-
enrolled IDUs who were HIV-negative at the preceding
MMTP enrollment was 0.53/100 PYAR, which is 74
times higher than that among the general population
[14]. High incidences of HCV and HIV among IDUs
who discontinued methadone treatment suggest that
HCV and HIV transmission among IDUs in Taipei
remains a serious concern. Prior studies showed that
interruptions to methadone treatment were associated
with increased prevalence of injecting drugs and sharing
syringes [33], which could raise risks of HCV and HIV
infection. Such findings support recommendations to
provide HCV and HIV risk reduction counseling, includ-
ing messages on safe injecting, to IDUs at MMTP
enrollment.
Caution is required in interpreting the results of this
study. First, we analyzed secondary data; information on
the sexual behaviors and occupation of the study partici-
pants was not available. However, the sexual behavior of
the participants is not likely to have confounded the
main findings on risk factors associated with HCV
mono-infection and HCV/HIV co-infection because
HCV transmission via risky sexual behavior is not com-
mon [34]. Second, the use of cross-sectional data, with-
out information on the temporal sequence between risk
behaviors and infection of individual IDUs, precludes
causal inference. Third, it is difficult to obtain a truly
representative sample of a population of community-
dwelling IDUs. It has been estimated that MMTP parti-
cipants accounted for fewer than 20% of reported
heroin-addicted drug users in Taipei in 2010 [14]. Thus,
the generalizability of the present findings might be lim-
ited to IDUs at the Taipei MMTP.Conclusions
This appears to be the first study to estimate sero-
prevalence and seroincidence of HCV/HIV co-infection
and HCV mono-infection among IDUs at an MMTP in
Taipei. IDUs at a Taipei MMTP had a very high preva-
lence of HCV/HIV co-infection and HCV mono-infec-
tion. Interventions such as expansion of syringe
exchange programs and education on HCV/HIV preven-
tion must be implemented for this high-risk group of
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